NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis $49.02 -0.11 (-0.22%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rhythm Pharmaceuticals alerts:Sign Up Key Stats Today's Range$48.17▼$49.6350-Day Range$44.19▼$54.5552-Week Range$21.34▼$55.64Volume387,359 shsAverage Volume533,367 shsMarket Capitalization$3.00 billionP/E RatioN/ADividend YieldN/APrice Target$60.33Consensus RatingModerate Buy Company OverviewRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Rhythm Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks77th Percentile Overall ScoreRYTM MarketRank™: Rhythm Pharmaceuticals scored higher than 77% of companies evaluated by MarketBeat, and ranked 244th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRhythm Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rhythm Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.43) to ($2.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -11.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -11.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 17.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rhythm Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.46% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 19.1, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently decreased by 11.88%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.80 Percentage of Shares Shorted13.46% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 19.1, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently decreased by 11.88%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.26 News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Rhythm Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,393,885.00 in company stock.Percentage Held by InsidersOnly 5.60% of the stock of Rhythm Pharmaceuticals is held by insiders.Read more about Rhythm Pharmaceuticals' insider trading history. Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Stock News HeadlinesSonam Kapoor And Anand Ahuja Buy Mumbai’s Iconic Rhythm House Worth Rs 478 Cr: ReportOctober 24 at 2:33 AM | msn.comGuggenheim Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)October 24 at 2:03 AM | americanbankingnews.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Sonam Kapoor, Anand Ahuja Buy Nirav Modi's Music Store Rhythm House For ₹47.8 Crore In MumbaiOctober 23 at 6:58 AM | msn.com‘Sorry 4 That Much’ Takes Feid to No. 1 on Latin Rhythm AirplayOctober 23 at 1:58 AM | yahoo.comOnce owned by Nirav Modi, Sonam Kapoor snaps up Mumbai’s famed Rhythm House for ₹47.8 croreOctober 23 at 1:58 AM | msn.comSamsung Galaxy Watch series in Malaysia finally gets Irregular Heart Rhythm Notification featureOctober 21 at 7:52 AM | msn.comThe official trailer for “Rhythm + Flow” season 2 goes liveOctober 19, 2024 | yahoo.comSee More Headlines RYTM Stock Analysis - Frequently Asked Questions How have RYTM shares performed this year? Rhythm Pharmaceuticals' stock was trading at $45.97 on January 1st, 2024. Since then, RYTM shares have increased by 6.6% and is now trading at $49.02. View the best growth stocks for 2024 here. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $0.16. Rhythm Pharmaceuticals's revenue was up 51.3% compared to the same quarter last year. When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' top institutional investors include Hennion & Walsh Asset Management Inc. (0.17%), Wedge Capital Management L L P NC (0.08%), Assenagon Asset Management S.A. (0.03%) and Handelsbanken Fonder AB (0.03%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Pamela J Cramer, William T Roberts, Jennifer Chien, Jennifer L Good, Lynn A Tetrault, Jennifer Kayden Lee, Christopher Paul German and Joseph Shulman. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/06/2024Today10/24/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RYTM CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$60.33 High Stock Price Target$79.00 Low Stock Price Target$52.00 Potential Upside/Downside+23.1%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($4.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,680,000.00 Net Margins-254.88% Pretax Margin-253.57% Return on Equity-221.65% Return on Assets-78.17% Debt Debt-to-Equity RatioN/A Current Ratio6.53 Quick Ratio6.31 Sales & Book Value Annual Sales$77.43 million Price / Sales38.70 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book17.08Miscellaneous Outstanding Shares61,130,000Free Float57,710,000Market Cap$3.00 billion OptionableOptionable Beta2.07 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:RYTM) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.